

European Congress on HEMATOLOGY

June 14-15, 2021 | Webinar

Management of pregnant patients with a history of thrombotic complications**Lucia Stanciakova¹, Dobrotova M., ¹Holly P, ²Bolek T, ²Samos M, ¹Kubisz P, ¹Stasko**¹National Centre of Haemostasis and Thrombosis, Department of Haematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Martin, Slovakia²Department of Internal Medicine I, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Martin, Slovakia

Statement of the Problem: Thrombophilia can aggravate the prothrombotic state developed during pregnancy and increase the risk of thromboembolic and pregnancy complications, especially in patients with a history of thrombotic event. Guidelines of the American College of Chest Physicians (ACCP) prefer the use of secondary anticoagulant thromboprophylaxis with low molecular weight heparin (LMWH). It is supposed that such antithrombotic prevention provides also antiinflammatory and immunomodulatory effect.

Methodology & Theoretical Orientation: The authors present the results obtained in the course of the prospective longitudinal monitoring of changes in haemostasis in high-risk pregnant women.

Findings: During 4 consecutive blood samplings during pregnancy (T1-T4) and 1 after the postpartum period (T5), the results of standard coagulation tests shortened significantly up to the delivery, D-dimer and fibrinogen levels increased and specialized tests of changes in haemostasis (increased FVIII activity, decreased PS function and ProC Global ratio not normalized after the postpartum period) also confirmed the activation of haemostasis despite the use of LMWH.

Conclusion & Significance: The combination of the results of the above-mentioned tests, anti-Xa activity and clinical state of the patients enabled individualized adjustment of the dose of LMWH according to the actual parameters.

Biography

Lucia Stanciakova was awarded the degree Doctor of Medicine in 2013 and completed her postgraduate study in 2017. Now she works as a haematologist and assistant lecturer at the National Centre of Haemostasis and Thrombosis, Department of Haematology and Transfusion Medicine, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Slovakia. Her research interest includes thrombophilic states and their genetics, haemostasis in vascular disorders and oncological diseases, high-risk pregnancy, monitoring of the effectiveness of direct oral anticoagulants and antiplatelet treatment. She is a member of Slovak Society for Haemostasis and Thrombosis, previous Overseas Fellow of The Royal Society of Medicine and a member of the International Society on Thrombosis and Haemostasis. Dr. Stanciakova won the 2015 Eberhard F. Mammen Young Investigator Award of the Seminars in Thrombosis and Hemostasis and Young Investigator Award of the 18th International Meeting of Danubian League against Thrombosis and Haemorrhagic Disorders.

stanciakova2@uniba.sk